2 Governance Report of the Directors The Directors present their annual report on the affairs of within the daily NAV per share calculation as required and in the Company together with the audited financial statements accordance with generally accepted accounting standards.
and the Independent Auditors Report for the year ended In order to ensure that only sustained outperformance is 31 March 2016. rewarded, at each quarterly calculation date any performance fee payable is based on the lower of: Significant agreements i The cumulative outperformance of the portfolio over the Details of the services provided under these agreements are Benchmark as at the quarter end date: and included in the Strategic Report on page 18. ii The cumulative outperformance of the portfolio over the Alternative Investment Fund Management Benchmark as at the corresponding quarter end date in the agreement previous year.
As described on page 18, Frostrow is the designated AIFM for The effect of this is that outperformance has to be maintained the Company on the terms and subject to the conditions of the for a twelve month period before it is paid.
alternative investment fund management agreement between In addition, a performance fee only becomes payable to the the Company and Frostrow the AIFM Agreement.
extent that the cumulative outperformance gives rise to a total The notice period on the AIFM Agreement with Frostrow is fee greater than the total of all performance fees paid to date.
12 months, termination can be initiated by either party.
No provision for potential future performance fee payments Frostrow charge a variable base fee, which is dependent on has been made as at 31 March 2016.
As at 31 March 2015 a the size of the Company further details can be found on provision of 16.7m had been made, of which 11.2m page 18 and a performance fee of 1.5% of outperformance became payable due to continued cumulative outperformance against the Benchmark as set out below.
in the three quarters to 31 December 2015.
Following underperformance in the quarter to 31 March 2016, 5.5m Portfolio management agreement of the provision was reversed as shown in note 3 on page 55.
Under the AIFM Agreement Frostrow has delegated the The maximum amount that could become payable by 31 March portfolio management function to OrbiMed, under a portfolio 2017, in the event that the last quarters underperformance is management agreement between it, the Company and reversed and outperformance achieved is 12.8m.
Frostrow the Portfolio Management Agreement.
Depositary agreement OrbiMed receives a periodic fee equal to 0.65% p. a. of the The Company appointed J. P. Morgan Europe Limited the Companys NAV and a performance fee as set out in the Depositary as its Depositary in accordance with the Performance Fee section below.
Its agreement with the AIFMD on the terms and subject to the conditions of the Company may be terminated by either party giving notice of Depositary agreement between the Company, Frostrow and not less than 12 months.
the Depositary the Depositary Agreement.
Performance fee Under the terms of the Depositary Agreement the Company Dependent on the level of long-term outperformance of the has agreed to pay the Depositary a fee calculated at 1.75bp Company, OrbiMed and Frostrow are entitled to a on net assets up to 150 million, 1.50 bps on net assets performance fee.
The performance fee is calculated by between 150 million and 300 million 1.00bps on net assets reference to the amount by which the Companys NAV between 300 million and 500 million and 0.50bps on net performance has outperformed the Benchmark see inside assets above 500 million.
front cover for details of the Benchmark.
The Depositary has delegated the custody and safekeeping of The fee is calculated quarterly by comparing the cumulative the Companys assets to J. P. Morgan Clearing Corp the performance of the Companys NAV with the cumulative Prime Broker pursuant to a delegation agreement performance of the Benchmark since the launch of the between the Company, Frostrow, the Depositary and the Company in 1995.
The performance fee amounts to 16.5% of any Prime Broker the Delegation Agreement.
outperformance over the Benchmark, OrbiMed receiving 15% and Frostrow receiving 1.5% respectively.
Provision is also made Worldwide Healthcare Trust PLC 25 Annual Report for the year ended 31 March 2016 The Delegation Agreement transfers the Depositarys liability Agreement.
The Prime Broker receives interest on the for the loss of the Companys financial instruments held in drawn overdraft as detailed in note 12 on page 60. custody by the Prime Broker to the Prime Broker in The Prime Broker is a registered broker-dealer and is regulated accordance with the AIFMD.
The Company has consented to by the United States Securities and Exchange Commission.
the transfer and reuse of its assets by the Prime Broker Continuation of the Company known as rehypothecation in accordance with the terms of In accordance with the Companys Articles of Association, an institutional account agreement between the Company, shareholders will have an opportunity to vote on the the Prime Broker and certain other J. P. Morgan entities as continuation of the Company at the 2019 Annual General defined therein.
See page 20 for further details.
Meeting and every five years thereafter.
Prime brokerage agreement The Company appointed J. P. Morgan Clearing Corp the Results and dividends Prime Broker on the terms and subject to the conditions The results attributable to shareholders for the year and the of the prime brokerage agreement between the Company, transfer from reserves are shown on pages 49 to 51.
Details Frostrow and the Depositary the Prime Brokerage of the Companys dividend record can be found on page 2.
Substantial interests in share capital The Company was aware of the following substantial interests in the voting rights of the Company as at 31 May 2016, the latest practicable date before publication of the Annual Report: 31 May 2016 31 March 2016 Number of % of issued Number of % of issued Shareholder shares share capital shares share capital Investec Wealth & Investment Limited 5,733,954 11.99 5,786,468 12.2 Alliance Trust Savings Limited 2,569,041 5.4 2,427,415 5.1 Rathbone Brothers plc 2,544,547 5.3 2,544,522 5.3 Speirs & Jeffrey Limited 1,928,470 4.0 1,901,313 4.0 Charles Stanley & Co Limited 1,901,814 4.0 1,935,289 4.1 Hargreaves Lansdown plc 1,789,724 3.7 1,840,622 3.9 Brewin Dolphin Limited 1,660,065 3.5 1,689,964 3.6 Quilter Cheviot Limited 1,600,375 3.4 1,592,602 3.4 As at 31 March 2016 the Company had 47,640,045 shares in issue excluding 198,975 shares held in treasury.
As at 31 May 2016 the Company had 47,308,593 shares in issue excluding 530,427 shares held in treasury.
Beneficial owners of shares information Directors indemnities During the year under review and to the date of this report, rights indemnities were in force between the Company and each of its Beneficial owners of shares who have been nominated by Directors under which the Company has agreed to indemnify the registered holder of those shares to receive information each Director, to the extent permitted by law, in respect of rights under section 146 of the Companies Act 2006 are certain liabilities incurred as a result of carrying out his or her required to direct all communications to the registered role as a Director of the Company.
The Directors are also holder of their shares rather than to the Companys indemnified against the costs of defending any criminal or civil registrar, Capita Asset Services, or to the Company directly.
proceedings or any claim by the Company or a regulator as they Directors & officers liability insurance cover are incurred provided that where the defence is unsuccessful Directors & officers liability insurance cover was the Director must repay those defence costs to the Company.
maintained by the Company during the year ended 31 March The indemnities are qualifying third party indemnity provisions 2016.
It is intended that this policy will continue for the year for the purposes of the Companies Act 2006. ending 31 March 2017 and subsequent years.
Worldwide Healthcare Trust PLC Annual Report for the year ended 31 March 2016 26 2 Governance Report of the Directors continued A copy of each deed of indemnity is available for inspection Global greenhouse gas emissions at the Companys registered office during normal business The Company has no greenhouse gas emissions to report hours and will be available for inspection at the Annual from its operations, nor does it have responsibility for any General Meeting.
other emissions producing sources under Large and Medium sized Companies and Groups Accounts and Capital structure Reports Regulations 2008 as amended, including those The Companys capital structure is composed solely of Ordinary within our underlying investment portfolio.
Corporate governance Ordinary shares The Corporate Governance Statement set out on pages 29 to 36 forms part of the Report of the Directors.
During the year under review, 794,867 Ordinary Shares were bought back by the Company to be held in treasury at an Requirements of the Listing Rules average discount of 6.5% to the prevailing diluted ex income Listing Rule 9.8.
4 requires the Company to include certain NAV per share.
A total of 256,832 shares were then reissued information in a single identifiable section of the Annual from treasury during the year at an average discount of 2.9% Report or a cross reference table indicating where the to the prevailing diluted ex income NAV per share at the time information is set out.
The Directors confirm that there are of issue, resulting in a net gain to the Company of 66,000. no disclosures to be made in this regard.
339,060 Ordinary Shares held in treasury were cancelled by the Company on 24 September 2015.
By order of the Board Since the year end 615,099 Ordinary Shares were bought back into treasury at an average discount of 7.2% to the prevailing ex income NAV per share.
Frostrow Capital LLP Company Secretary Voting rights in the Companys ordinary shares Details of the voting rights in the Companys ordinary shares 14 June 2016 at the date of this Annual Report are given in note 9 to the Notice of Annual General Meeting on page 76.
Political and charitable donations The Company has not in the past and does not intend in the future to make political or charitable donations.
Worldwide Healthcare Trust PLC 27 Annual Report for the year ended 31 March 2016
